
Mandolin
AI workers from Mandolin integrate seamlessly into existing EHR systems, optimizing infusion center operations.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
N/A | €0.0 | round | |
* | $32.0m | Series A | |
Total Funding | 000k |
Related Content
Mandolin operates as a healthcare technology firm focused on the specialty pharmaceutical market, providing an AI-driven automation platform to streamline administrative processes for accessing life-saving drugs. The company was established in 2024 by CEO Will Yin and COO Rohit Rustagi, repeat entrepreneurs who dropped out of Stanford. Their direction for the company was influenced by personal experiences with family members who struggled with delays in accessing specialty treatments for conditions like cancer and Alzheimer's.
The business targets the significant administrative bottlenecks in the healthcare system, particularly within infusion centers, specialty pharmacies, and health systems. Clients include large providers like Vivo Infusion, FlexCare Infusion, TwelveStone Health Partners, and Amber Specialty Pharmacy, with the platform deployed in over 700 clinic locations, serving more than 250,000 new patients annually. Mandolin's business model is centered on providing its AI platform to automate the end-to-end administrative tasks associated with infused and injected drugs, from patient referral to reimbursement.
Mandolin's core offering is a platform of AI agents that function as a digital workforce. These agents integrate directly into existing Electronic Health Records (EHRs), payer portals, and manufacturer hubs. The technology is designed to handle a variety of complex back-office tasks, such as performing benefits verification, navigating insurance portals, submitting prior authorizations, parsing faxes and clinical notes, and managing billing and claims. By automating these traditionally manual and time-consuming workflows, Mandolin aims to reduce treatment delays from weeks to days, lower operational costs for providers, and improve revenue cycle management. The company has secured significant financial backing, raising $40 million in a funding round from investors including Greylock Partners, SignalFire, Maverick, and SV Angel.
Keywords: specialty drug access, healthcare automation, AI agents, patient access platform, infusion center software, prior authorization automation, revenue cycle management, benefits verification, healthcare AI, specialty pharmacy solutions, EHR integration, clinical workflow automation, drug reimbursement, health tech, back-office automation, patient intake management, medical billing AI, care coordination, specialty therapies, pharmaceutical services